Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies.

Trial Profile

Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Donepezil (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 14 May 2015 Status changed from planning to recruiting as reported by ClinicalTrials.gov record.
    • 24 Sep 2014 Status changed from not stated to planning.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top